Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as hyaluronan
Synvisc · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Synvisc | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Synvisc (hylan G-F 20) | DEVICE | - |
| Synvisc | DEVICE | intra-articular, 3 weekly injections |
Inclusion Criteria: * Patients with symptomatic OA pain of shoulder (gleno-humeral) Exclusion Criteria: * Patients with current or prior conditions or treatment that would impede measurement of efficacy or safety
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Synvisc is used for osteoarthritis, including osteoarthritis of the hip, shoulder, and ankle. It is a viscosupplementation product being studied in Phase 3 clinical trials for these indications. The drug is developed by Sanofi and is intended to treat pain and improve joint function in patients with osteoarthritis.
Synvisc is a viscosupplementation product that targets osteoarthritis by supplementing the synovial fluid in joints. It is designed to restore the viscoelastic properties of the joint fluid, which can become degraded in osteoarthritis. This helps to lubricate the joint and act as a shock absorber, potentially reducing pain and improving mobility.
Synvisc is developed by Sanofi, a multinational pharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical trials to evaluate the safety and efficacy of Synvisc in treating osteoarthritis in various joints, including the hip, shoulder, and ankle.
Synvisc is in Phase 3 clinical development for osteoarthritis. It has completed three Phase 3 trials, which studied its safety and efficacy in patients with symptomatic shoulder osteoarthritis, osteoarthritis of the hip, and symptomatic ankle osteoarthritis. These trials were randomized, double-blind, and placebo-controlled, and they have been completed.
Synvisc has been studied in three completed Phase 3 clinical trials: NCT00131300 for shoulder osteoarthritis, NCT00131326 for hip osteoarthritis, and NCT00131768 for ankle osteoarthritis. Additionally, a Phase 1 trial (NCT00949494) examined its effects on cartilage in knee osteoarthritis. All trials are completed, with no active trials currently ongoing.
Synvisc is not known to be the same as any other drug, as no alternative names have been reported. It is a distinct viscosupplementation product developed by Sanofi for the treatment of osteoarthritis. Its unique formulation is being evaluated in clinical trials for its safety and efficacy in various joints.